Company Profile
Updated: 26-OCT-09Amsterdam Molecular Therapeutics Holding N.V.
International public company
Postbus 22506, Meibergdreef 61, Amsterdam, NL-1100 DA, Netherlands
()31 020 566 73 94, 31 020 566 92 72 fax, http://www.amtbiopharma.com
Primary SIC: Commercial Physical & Bio Research, Primary NAICS: Research and Development in the Physical Sciences and Engineering Sciences
Description: Services: Provision of product development services for virus-based therapeutics. The major products of the company include an adeno-associated virus based gene therapy for the treatment of lipoprotein lipase deficiency and a cell-based product for the treatment of Crohn's disease
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Amsterdam Molecular Therapeutics Announces Pricing of Initial Public Offering (IPO) on Euronext Amsterdam.
Business Wire; 6/20/2007; 2391 words; ...time Introduction Amsterdam Molecular Therapeutics (AMT) Holding B.V. (to be converted today into a public company with limited liability, Amsterdam Molecular Therapeutics (AMT) Holding N.V.) ("AMT"), a Dutch company active...
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning
